(Health Korea News / Lee Chang-yong) At the ‘Tanamin Launching Symposium’ hosted by Dong-A ST, approximately 600 medical professionals discussed ‘Tanamin’, a brain and peripheral circulation improvement agent, from an academic perspective.
Dong-A ST successfully completed the ‘Tanamin Launching Symposium’ held in nine major cities across the country from May to July. At the symposium, the medical team shared the latest knowledge and treatment strategies for cerebrovascular and peripheral vascular diseases.
The symposium held in Busan was chaired by Professor Cha Jae-gwan of the Department of Neurology at Dong-A University Hospital. Professor Seo Jeong-hwa of the Department of Neurology at Busan Baek Hospital and Professor Ahn Seong-ho of the Department of Neurology at Yangsan Pusan National University Hospital gave lectures.
In his lecture titled ‘How to manage Cognitive Impairment with EGb 761’, Professor Seo introduced the benefits of tanamine, which can help reduce NeuroInflammation in patients with cognitive impairment and prevent cognitive decline.
Professor Ahn gave a lecture on the topic of ‘Management of Dizziness and Vertigo with TANAMIM’ and talked about the effect of Tanamin on dizziness in patients with cerebrovascular disease.
Tanaminjeong is a brain and peripheral circulation improvement agent made with EGb761®, the original dried extract of ginkgo leaves developed and standardized for the first time in the world by the German Schwabe Group, as its active ingredient. It is effective for organic brain dysfunction accompanied by dementia symptoms (e.g. memory loss), dizziness, peripheral arterial circulation disorder (intermittent claudication), and vascular and degenerative tinnitus.
Symposium moderator Professor Cha Jae-gwan said, “I think that Tanamin is a useful medicine to prescribe first to patients with mild cognitive impairment, improved vascular function, and dizziness,” and “In particular, Tanamin is recommended in various guidelines and is a medicine with few side effects.”
A Dong-A ST official said, “Through this symposium, we were able to confirm the excellence and necessity of Tanamin in the treatment of cerebral and peripheral blood vessels,” and “We hope that Tanamin, which has emerged as a new option for the treatment of cerebral and peripheral blood vessels, will help improve the quality of life of patients.”
The Tanamin Launching Symposium began in Seoul and then moved on to Gwangju, Daejeon, Ansan, Pangyo, Incheon, Daegu, Jeonju, and concluded with the symposium in Busan.
Dong-A ST previously signed a joint sales contract with Yuyu Pharmaceutical for the brain and peripheral circulation improvement drug ‘Tanamin tablet’ in March. The two companies are conducting sales and marketing activities for Tanamin tablet together. Dong-A ST and Yuyu Pharmaceutical are jointly responsible for sales targeting general hospitals. Dong-A ST is in charge of sales targeting hospitals and clinics.
Copyright © Health Korea News. Unauthorized reproduction and redistribution prohibited.
Source: www.hkn24.com
